The synthesis of a novel molecular imaging probe 68Ga-DOTA-PDL1P and application in mouse model of melanoma

doi:10.19401/j.cnki.1007-3639.2023.04.005

Abstract

Abstract:

Background and purpose: The immunogenic drugs represented by programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) have achieved great success in clinic. However, with the development of clinical application, the overall effective rate varies greatly. At present, detection of the expression of PD-1/PD-L1 before the start of tumor treatment is an important basis for clinical medication. However, the current detection method of PD-L1 expression requires the acquisition of patient specimens, which is traumatic. Therefore, there is an urgent need to develop a noninvasive method to detect PD-L1 expression in vivo. This study innovatively designed and synthesized a new positron emission tomography (PET) imaging agent targeting PD-L1 polypeptide ⁶⁸Ga-DOTA-PDL1P. In this study, the labeling rate, radiochemical purity and stability of ⁶⁸Ga-DOTA-PDL1P were evaluated for quality control. And the application was evaluated in the mouse model of melanoma in order to obtain a promising ⁶⁸Ga-DOTA-PDL1P immune PET probe. Methods: Gallium-68 (⁶⁸Ga) was used to label DOTA-PDL1P, and its radiochemical purity and stability were evaluated by quality control. To evaluate its specific targeting performance, the cell uptake and blocking experiments were carried out in murine melanoma B16-F10 cells. The biodistribution experiment was performed in B16-F10 tumor-bearing mice to analyze the metabolism of the PET imaging agent in vivo. The Tumor uptake of ⁶⁸Ga-DOTA-PDL1P in B16-F10 tumor-bearing mice was observed by PET/CT imaging, and the tumor/muscle (T/M) ratio was semi-quantitatively analyzed. In addition, radioautography was performed to further analyze the tumor uptake of ⁶⁸Ga-DOTA-PDL1P probe. Tumor cell proportion score (TPS) and combined positive score (CPS) were used to analyze the immunohistochemical staining results to evaluate the expression of PD-L1 in tumor tissues. Results: The labeling efficiency and radiochemical purity of ⁶⁸Ga-DOTA-PDL1P were more than 99%, and the radiochemical purity of ⁶⁸Ga-DOTA-PDL1P was more than 90% after 3 h of incubation in PBS and fetal bovine serum. Cellular uptake results showed that ⁶⁸Ga-DOTA-PDL1P could be specifically taken up by B16-F10 cells, and the specific uptake could be blocked by PD-L1P peptide competitive binding. Biodistribution assay showed that ⁶⁸Ga-DOTA-PDL1P was mainly excreted through the urinary system. The results of microPET/CT imaging of tumor-bearing mice showed a high uptake of ⁶⁸Ga-DOTA-PDL1P in tumor tissues, and the T/M ratio was 6.7. The autoradiography results confirmed that ⁶⁸Ga-DOTA-PDL1P high uptake in the tumor was consistent with the PD-L1 positive area of immunohistochemical staining, which proved that ⁶⁸Ga-DOTA-PDL1P could specifically bind to PD-L1 positive malignant tumor cells. Conclusion: The novel ⁶⁸Ga-DOTA-PDL1P PET imaging agent synthesized in this study has good stability and can specifically target PD-L1 positive tumor cells, which is a promising new immune PET probe targeting PD-L1 protein.

Key words: PD-L1, Malignant melanoma, ⁶⁸Ga, PET/CT

CLC Number:

R730.44

YANG Ziyi, LI Panli, GU Bingxin, LIU Cheng, SONG Shaoli, XU Xiaoping. The synthesis of a novel molecular imaging probe ⁶⁸Ga-DOTA-PDL1P and application in mouse model of melanoma[J]. China Oncology, 2023, 33(4): 354-360.

Figures/Tables 5

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

References 23

[1]	HERBST R S, SORIA J C, KOWANETZ M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528): 563-567. doi: 10.1038/nature14011
[2]	ZAK K M, KITEL R, PRZETOCKA S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1[J]. Structure, 2015, 23(12): 2341-2348. doi: S0969-2126(15)00402-5 pmid: 26602187
[3]	SAKUISHI K, APETOH L, SULLIVAN J M, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity[J]. J Exp Med, 2010, 207(10): 2187-2194. doi: 10.1084/jem.20100643
[4]	SCHADENDORF D, VAN AKKOOI A C J, BERKING C, et al. Melanoma[J]. Lancet, 2018, 392(10151): 971-984. doi: S0140-6736(18)31559-9 pmid: 30238891
[5]	DIKA, PATRIZI A, LAMBERTINI M, et al. Estrogen receptors and melanoma: a review[J]. Cells, 2019, 8(11): 1463. doi: 10.3390/cells8111463
[6]	MILLER K D, NOGUEIRA L, DEVASIA T, et al. Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436. doi: 10.3322/caac.v72.5
[7]	GERSHENWALD J E, SCOLYER R A, HESS K R, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(6): 472-492. doi: 10.3322/caac.21409
[8]	EGGERMONT A M M, DUMMER R. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients[J]. Eur J Cancer, 2017, 86: 101-105. doi: S0959-8049(17)31295-9 pmid: 28968566
[9]	HOMET MORENO B, RIBAS A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers[J]. Br J Cancer, 2015, 112(9): 1421-1427. doi: 10.1038/bjc.2015.124
[10]	GARON E B, RIZVI N A, HUI R N, et al. Pembrolizumab for the treatment of non-small cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-2028. doi: 10.1056/NEJMoa1501824
[11]	VAZ S C, OLIVEIRA F, HERRMANN K, et al. Nuclear medicine and molecular imaging advances in the 21st century[J]. Br J Radiol, 2020, 93(1110): 20200095. doi: 10.1259/bjr.20200095
[12]	张倩, 丁缙, 任亚楠, 等. 靶向血管紧张素转化酶2新型PET探针的制备及其肿瘤特异性分子显像[J]. 中华核医学与分子影像杂志, 2021, 41(10): 580-584.
	ZHANG Q, DING J, REN Y N, et al. Preparation and tumor-specific molecular imaging of a novel PET probe targeting angiotensin converting enzyme 2[J]. Chin J Nucl Med Mol Imaging, 2021, 41(10): 580-584.
[13]	CHATTERJEE S, LESNIAK W G, MILLER M S, et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide[J]. Biochem Biophys Res Commun, 2017, 483(1): 258-263. doi: 10.1016/j.bbrc.2016.12.156
[14]	DE SILVA R A, KUMAR D, LISOK A, et al. Peptide-based ⁶⁸Ga-PET radiotracer for imaging PD-L1 expression in cancer[J]. Mol Pharm, 2018, 15(9): 3946-3952. doi: 10.1021/acs.molpharmaceut.8b00399
[15]	LESNIAK W G, MEASE R C, CHATTERJEE S, et al. Development of[¹⁸F]FPy-WL12 as a PD-L1 specific PET imaging peptide[J]. Mol Imaging, 2019, 18: 1536012119852189.
[16]	赵亮, 富凯丽, 姚兰琳, 等. 整合素α vβ 3放射性核素靶向治疗联合PD-L1免疫治疗的实验研究[J]. 中华核医学与分子影像杂志, 2020, 40(5): 268-274.
	ZHAO L, FU K L, YAO L L, et al. Enhancement of therapeutic efficacy by combination of integrin α vβ 3-targeted radiotherapy and anti-PD-L1 immunotherapy: a preclinical study[J]. Chin J Nucl Med Mol Imaging, 2020, 40(5): 268-274.
[17]	CHANG H N, LIU B Y, QI Y K, et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy[J]. Angew Chem Int Ed Engl, 2015, 54(40): 11760-11764. doi: 10.1002/anie.v54.40
[18]	SUN S Y, FEI X C, MAO Y, et al. PD-1( + ) immune cell infiltration inversely correlates with survival of operable breast cancer patients[J]. Cancer Immunol Immunother, 2014, 63(4): 395-406. doi: 10.1007/s00262-014-1519-x
[19]	AHMADZADEH M, JOHNSON L A, HEEMSKERK B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired[J]. Blood, 2009, 114(8): 1537-1544. doi: 10.1182/blood-2008-12-195792 pmid: 19423728
[20]	HAWKES E A, GRIGG A, CHONG G. Programmed cell death-1 inhibition in lymphoma[J]. Lancet Oncol, 2015, 16(5): e234-e245. doi: 10.1016/S1470-2045(15)70103-8
[21]	MAHONEY K M, FREEMAN G J, MCDERMOTT D F. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma[J]. Clin Ther, 2015, 37(4): 764-782. doi: 10.1016/j.clinthera.2015.02.018 pmid: 25823918
[22]	孙艳莎, 宋少莉. 核素标记的PD-1与PD-L1显像剂在肿瘤诊断中的研究进展[J]. 中华核医学与分子影像杂志, 2019, 39(2): 108-111.
	SUN Y S, SONG S L. Research progress of radionuclide labeled imaging agents targeting PD-1 and PD-L1 in the diagnosis of tumors[J]. Chin J Nucl Med Mol Imaging, 2019, 39(2): 108-111.
[23]	HUANG Z L, JIN Y, CAI X, et al. Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer[J]. Thorac Cancer, 2022, 13(4): 523-532. doi: 10.1111/tca.v13.4

The synthesis of a novel molecular imaging probe ⁶⁸Ga-DOTA-PDL1P and application in mouse model of melanoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 23

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	MA Guang, OU Xiaomin, HU Chaosu, SONG Shaoli, YANG Zhongyi. Value of pretreatment ¹⁸F-FLT PET/CT and ¹⁸F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma [J]. China Oncology, 2022, 32(4): 309-315.
[2]	ZOU Zijian, SUN Wei, HU Tu, WANG Chunmeng, YAN Wangjun, LUO Zhiguo, LIU Xin, ZHONG Jingqin, LIN Xinyi, XU Yu, CHEN Yong. Clinical value of sentinel lymph node biopsy in patients with cutaneous and acral melanoma [J]. China Oncology, 2022, 32(12): 1168-1177.
[3]	JIA Dongdong, LI Tao. Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma [J]. China Oncology, 2022, 32(12): 1178-1183.
[4]	HU Guannan , CHEN Lei , ZHOU Liangping , ZHOU Zhengrong . A case report of pulmonary malignant melanoma complicated with lung adenocarcinoma and literature review [J]. China Oncology, 2021, 31(7): 647-650.
[5]	SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao . Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism [J]. China Oncology, 2021, 31(4): 308-316.
[6]	WANG Jing, CHEN Jie, HU Chun, HUANG Cheng. PI3K/AKT regulates the expression of PD-L1 via Nrf2 pathway in non-small cell lung cancer [J]. China Oncology, 2020, 30(6): 419-427.
[7]	LI Zeng, LIAO Hong, MAO Dun, WU Yi, XIAO Yingming, YANG Shengke, ZHONG Lei, ZHOU Shukui, CHEN Yongji. The value of ¹⁸ F-PSMA-1007 PET/CT in accurate assessment of newly diagnosed prostate cancer and its impact on clinical treatment decisions [J]. China Oncology, 2020, 30(3): 231-236.
[8]	ZHOU Hongyu, CHEN Lihua, LI Haoran, CHENG Xi. The role of c-kit in the treatment and prognosis of primary female genital malignant melanoma: current status and prospects [J]. China Oncology, 2020, 30(10): 834-840.
[9]	REN Wenjia , ZHOU Min , WU Shixiu , CHEN Junqiang , CHEN Yanan , CHEN Weiwei , AI Tashan , CHEN Yun , JIANG Guoliang , ZHAO Kuaile . Prognostic and predictive value of ¹⁸F-FLT PET/CT in patients with esophageal squamous carcinoma treated by radiochemotherapy [J]. China Oncology, 2019, 29(12): 965-970.
[10]	QIN Lanqun , ZOU Zhengyun . Advances in personalized tumor vaccine for malignant melanoma [J]. China Oncology, 2019, 29(11): 906-909.
[11]	ZHENG Yingying,XU Junyan,ZHANG Jianping, et al. The value of ¹⁸F-FDG PET/CT texture analysis in predicting neoadjuvant chemoradiotherapy of locally advanced rectal cancer [J]. China Oncology, 2018, 28(8): 590-594.
[12]	ZHANG Yingqiang, ZHANG Xin, WANG Chen, et al. The value of ¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy [J]. China Oncology, 2018, 28(7): 505-510.
[13]	. Evaluating the change of fatty acid synthesis in renal cell carcinoma by 18F-FAC microPET/CT imaging [J]. China Oncology, 2018, 28(5): 327-334.
[14]	CAO Dalong, YE Dingwei. Advances and future prospects of immunotherapy in bladder cancer [J]. China Oncology, 2018, 28(2): 81-87.
[15]	ZHAO Haiyun, JI Peng, LI Xiaoguang, et al. Research progress of biomarkers associated with efficacy of immune checkpoint blockade [J]. China Oncology, 2018, 28(11): 852-857.